The cancer-immunity cycle: Indication, genotype, and immunotype
The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …
treatment of malignancies across a broad range of indications. Whereas initially, single …
Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …
cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a …
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology
LGN de Almeida, H Thode, Y Eslambolchi… - Pharmacological …, 2022 - Elsevier
The first matrix metalloproteinase (MMP) was discovered in 1962 from the tail of a tadpole by
its ability to degrade collagen. As their name suggests, matrix metalloproteinases are …
its ability to degrade collagen. As their name suggests, matrix metalloproteinases are …
Tertiary lymphoid structures in cancer
BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …
Targeting the gut and tumor microbiota in cancer
Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
sha** cancer immunosurveillance and response to immunotherapy. Our understanding of …
sha** cancer immunosurveillance and response to immunotherapy. Our understanding of …
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …
Neoadjuvant relatlimab and nivolumab in resectable melanoma
RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross… - Nature, 2022 - nature.com
Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …